📊 ALLO Key Takeaways
Is Allogene Therapeutics, Inc. (ALLO) a Good Investment?
Allogene is a pre-commercial biotech company with zero revenue and operating losses of $46.1M, burning $12.9M quarterly with only 2-3 quarters of cash runway remaining. While the balance sheet shows $278.9M equity and $396M assets with minimal debt, the company lacks a visible path to revenue generation and is fundamentally unsustainable without significant external funding or rapid product commercialization.
Allogene Therapeutics shows a weak fundamental profile: revenue fell to zero, losses remain very large, and free cash flow is deeply negative, indicating the business is still far from self-sustaining. While the balance sheet has no long-term debt and strong headline liquidity ratios, the current cash balance appears thin relative to annual operating cash burn, increasing dependence on future financing.
Allogene Therapeutics, Inc. Key Strengths (ALLO)
- Strong balance sheet with $278.9M stockholders equity and $396M total assets
- Excellent liquidity position with 9.65x current ratio and zero debt burden
- Sufficient short-term cash runway of $30.3M to continue operations for 2-3 quarters
- Debt-free balance sheet reduces solvency risk from leverage
- High current and quick ratios indicate strong near-term balance sheet liquidity on paper
- Equity base of $292.54M provides some balance sheet cushion despite ongoing losses
ALLO Stock Risks: Allogene Therapeutics, Inc. Investment Risks
- Zero revenue with no commercially approved products indicates pre-clinical development stage with extreme clinical and regulatory risk
- Significant operating losses of $46.1M annually with negative free cash flow of $12.9M is unsustainable without external capital
- Limited cash runway of only 2-3 quarters at current burn rate creates existential refinancing urgency
- Biotech development risk: no guarantee of FDA approval, successful clinical trials, or commercialization success
- Zero revenue and persistent net losses signal no proven commercial engine
- Operating cash outflow of $149.25M materially exceeds cash and equivalents of $51.69M, implying funding pressure
- Negative ROE and ROA reflect poor capital efficiency and weak growth quality
Key Metrics to Watch
- Cash burn rate and runway extension through financing or revenue
- Clinical trial progression and regulatory milestones toward product approval
- Revenue recognition from any FDA-approved product launches
- Quarterly cash burn versus cash and equivalents
- Any return of product revenue or meaningful improvement in operating loss
Allogene Therapeutics, Inc. (ALLO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.65x current ratio provides a solid financial cushion.
ALLO Profit Margin, ROE & Profitability Analysis
ALLO vs Healthcare Sector: How Allogene Therapeutics, Inc. Compares
How Allogene Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Allogene Therapeutics, Inc. Stock Overvalued? ALLO Valuation Analysis 2026
Based on fundamental analysis, Allogene Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Allogene Therapeutics, Inc. Balance Sheet: ALLO Debt, Cash & Liquidity
ALLO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Allogene Therapeutics, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
ALLO Revenue Growth, EPS Growth & YoY Performance
ALLO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$41.4M | $-0.19 |
| Q2 2025 | N/A | -$50.9M | $-0.23 |
| Q1 2025 | N/A | -$59.7M | $-0.28 |
| Q3 2024 | N/A | -$62.3M | $-0.32 |
| Q2 2024 | N/A | -$65.0M | $-0.35 |
| Q1 2024 | $22.0K | -$65.0M | $-0.38 |
| Q3 2023 | $43.0K | -$61.3M | $-0.37 |
| Q2 2023 | $44.0K | -$74.8M | $-0.52 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Allogene Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALLO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Allogene Therapeutics, Inc. (CIK: 0001737287)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALLO
What is the AI rating for ALLO?
Allogene Therapeutics, Inc. (ALLO) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALLO's key strengths?
Claude: Strong balance sheet with $278.9M stockholders equity and $396M total assets. Excellent liquidity position with 9.65x current ratio and zero debt burden. ChatGPT: Debt-free balance sheet reduces solvency risk from leverage. High current and quick ratios indicate strong near-term balance sheet liquidity on paper.
What are the risks of investing in ALLO?
Claude: Zero revenue with no commercially approved products indicates pre-clinical development stage with extreme clinical and regulatory risk. Significant operating losses of $46.1M annually with negative free cash flow of $12.9M is unsustainable without external capital. ChatGPT: Zero revenue and persistent net losses signal no proven commercial engine. Operating cash outflow of $149.25M materially exceeds cash and equivalents of $51.69M, implying funding pressure.
What is ALLO's revenue and growth?
Allogene Therapeutics, Inc. reported revenue of $0.0.
Does ALLO pay dividends?
Allogene Therapeutics, Inc. does not currently pay dividends.
Where can I find ALLO SEC filings?
Official SEC filings for Allogene Therapeutics, Inc. (CIK: 0001737287) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALLO's EPS?
Allogene Therapeutics, Inc. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ALLO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Allogene Therapeutics, Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ALLO stock overvalued or undervalued?
Valuation metrics for ALLO: ROE of -15.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ALLO's AI grade for 2026?
Our dual AI analysis gives Allogene Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALLO's free cash flow?
Allogene Therapeutics, Inc.'s operating cash flow is $-12.9M, with capital expenditures of $9.0K.
How does ALLO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -15.3% (avg: 15%), current ratio 9.65 (avg: 2).